Eris Lifesciences is set to debut on the stock market tomorrow after concluding its initial public offer last week.
The company's IPO was oversubscribed 3.29 times during June 16-20.
The portion set aside for qualified institutional buyers (QIBs) was oversubscribed 4.68 times, non institutional investors 45 per cent and retail investors 3.51 times.
The price band for the share sale was fixed at Rs 600- 603.
The book running lead managers to the offer were Axis Capital, Citigroup Global Markets India and Credit Suisse Securities (India).
Eris Lifesciences is into manufacturing of branded pharmaceutical products in select therapeutic areas.
Disclaimer: No Business Standard Journalist was involved in creation of this content
